Luoxin Pharmaceutical’s LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023
(Adnkronos) – SHANGHAI, Oct. 23, 2023 /PRNewswire/ — From October 20 to 24, the 2023 ESMO Congress was held in Madrid, Spain. LX-039, an innovative anti-tumor drug developed by Luoxin Pharmaceuticals Group Stock
